[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368637-105":59,"doc-detail-368637-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-hmgb1-as-possible-marker-via-breast-organoid-cultures-research","Evaluation of HMGB1 as possible marker via breast organoid cultures research","","High mobility group box 1 (HMGB1) is an non-histone protein expressed in mammalian cell nuclei and can be released by both immune and tumor cells. Extracellular HMGB1 functions as a proinflammatory mediator that supports cancer progression. Using in vitro and molecular approaches, the study detects HMGB1 in breast cancer patient-derived organoids with elevated expression linked to worse prognosis. HMGB1 blockade in ex vivo 3D organoids induces cell cycle arrest and apoptosis. Immunofluorescence shows HMGB1, β-catenin, and NF-κB localization, and disabling HMGB1 signaling suppresses the pathway, indicating molecular crosstalk in inflammation-associated cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-hmgb1-as-possible-marker-via-breast-organoid-cultures-research/368637/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-hmgb1-as-possible-marker-via-breast-organoid-cultures-research/368637.png","ImageObject",300,407,{"name":92,"@type":93},"Chumphorn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is HMGB1 and why is it relevant to breast cancer?","Question",{"text":112,"@type":113},"HMGB1 is a non-histone chromatin protein that can be released by immune and tumor cells. Extracellular HMGB1 acts as a proinflammatory mediator and can support cancer progression, making it a potential marker and therapeutic target in breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was HMGB1 assessed in breast cancer organoid cultures?",{"text":117,"@type":113},"The study used in vitro protocols and molecular technologies to detect HMGB1 in organoids derived from breast cancer patients. HMGB1 localization was further examined by immunofluorescence.",{"name":119,"@type":110,"acceptedAnswer":120},"What happens when HMGB1 activity is blocked in the organoid models?",{"text":121,"@type":113},"Blocking HMGB1 protein activity in ex vivo 3D organoids results in cell cycle arrest and induction of apoptosis. Inhibiting HMGB1 signaling also suppresses the molecular pathway involving HMGB1-related molecules.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368637,1790386160,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},2336475401981,"https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694","ONCOLOGY REPORTS 54: 106, 2025  \nEvaluation of HMGB1 as possible marker via breast organoid cultures research  \nVINCENZA CIARAMELLA 1 , BARBARA CARRESE 1 , LUIGI COPPOLA 1 , GIOVANNI SMALDONE 1 , MASSIMILIANO D'AIUTO2 , GENNARO MOSSETTI3 , ANDREASORICELLI 1 and MARCO SALVATORE 1  \n1 2  \nIRCCS SYNLAB SDN, I‑80146 Naples, Italy; Clinica Villa Fiorita, I‑81031 Aversa, Italy; Pathological Anatomy Service, Maria Rosaria Clinic, Pompei, I‑80045 Naples, Italy  \n3  \nReceived November 20, 2024; Accepted March 11, 2025  \nDOI: 10. 3892/or.2025.8939  \nAbstract. High mobility group box 1 (HMGB1) is anon‑histone protein widely expressed in the nucleus of mammalian cells, and it can be released by both immune and tumor cells. In the extracellular context HMGB1 can act as aproinflammatory mediator and boosting cancer progression. High HMGB1 mRNA expression levels are usually observed in various malignant diseases, including breast cancer (BC) . Several studies have demonstrated the potential clinical value of HMGB1 in BC diagnosis and therapy. The present data, using in vitro protocols and molecular technologies, demonstrated the presence of HMGB1 in organoids derived from patients with BC with significantly elevated expression correlating with poorer prognosis. By blocking the activity of HMGB1 protein, cell cycle arrest and induction of apoptosis was observed in ex vivo 3D organoids, suggesting a potential antitumor effect. The localization by immunofluorescence, of HMGB1, β‑catenin and NF‑kB in organoids and the subse‑ quent inhibition of the entire molecular pathway by switching off HMGB1 signaling suggests that there is a crosstalk between these molecules demonstrating their involvement in inflamma‑ tion and inflammation‑associated diseases such as cancer. The current results aim to investigate the role of HMGB1 in BC progression and find innovative applications based on HMGB1 as a therapeutic target and early disease biomarker.  \nIntroduction  \nBreast cancer (BC) is one of the most prevalent cancers glob‑ ally with inter‑tumor and intra‑tumor variability. Several risk factors are linked to BC, including age, family history and genetic mutations (1) .  \nCorrespondence to: Dr Vincenza Ciaramella, IRCCS SYNLABSDN, 144 Via G. Ferraris, I‑80146 Naples, Italy  \nE‑mail: [vincenza.ciaramella@synlab.it](vincenza.ciaramella@synlab.it)  \nKey words: organoid, high mobility group box 1, breast cancer, biomarker  \nAdditional factors that may contribute to the develop‑ ment of BC, include obesity and hormone therapies (2) . The prevalence of BC has steadily increased over the past decade: Between 2010 and 2019, the incidence rate grew by 0.5% each year. In 2020, there were >2.3 million new BC cases diagnosed, resulting in ~685,000 deaths (3) . The diagnosis of BC involves a physical exam, imaging techniques such as mammography, and a tissue biopsy (4) . Overcoming therapy resistance necessitates exploring novel diagnostic proteins, such as high mobility group box 1 (HMGB1), in BC.  \nAmong them, HMGB1 protein, previously known asamphoterin, was discovered by Marco Emilio Bianchi's group in 1989 (5) . It is well known that HMGB1 is a struc‑ tural, non‑histone chromatin protein, a member of the High Mobility Group (HMG) protein family, specifically the HMGB subfamily, containing proteins with an HMG‑box DNA‑binding domain (6) . This protein is abundant in the nucleus of all eukaryotic cells, where it plays an important role in chromatin remodeling. It is also a key mediator of inflam‑ mation, particularly in the case of necrosis (7) . Furthermore, HMGB1 protein shows double function in cancer, serving both as an oncogene and a tumor suppressor, influencing cellular death and survival pathways, and it is involved in various stages of tumor progression, such as proliferation, invasion and metastasis (8) .  \nThe biological effects of HMGB1 are contingent upon its expression and subcellular location . When present within the nucleus, HMGB1 is involved in a m","cbCaidtqQMpQHC6c","https://ap.wps.com/l/cbCaidtqQMpQHC6c","pdf",2100703,"English","# Abstract\n# Introduction\n## Breast cancer background and clinical burden\n## HMGB1 biology and roles in cancer and inflammation\n## Cell cycle regulation and relevance to therapy\n## HMGB1 inhibitors and therapeutic implications","[{\"question\":\"What is HMGB1 and why is it relevant to breast cancer?\",\"answer\":\"HMGB1 is a non-histone chromatin protein that can be released by immune and tumor cells. Extracellular HMGB1 acts as a proinflammatory mediator and can support cancer progression, making it a potential marker and therapeutic target in breast cancer.\"},{\"question\":\"How was HMGB1 assessed in breast cancer organoid cultures?\",\"answer\":\"The study used in vitro protocols and molecular technologies to detect HMGB1 in organoids derived from breast cancer patients. HMGB1 localization was further examined by immunofluorescence.\"},{\"question\":\"What happens when HMGB1 activity is blocked in the organoid models?\",\"answer\":\"Blocking HMGB1 protein activity in ex vivo 3D organoids results in cell cycle arrest and induction of apoptosis. Inhibiting HMGB1 signaling also suppresses the molecular pathway involving HMGB1-related molecules.\"}]","Evaluation of HMGB1 as possible marker via breast organoid cultures research | PDF",1790177806,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/478be21f320aca621f0fa882ef9b61bf.webp",983,1357,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/743af41fd21050ac84a3c3a3362831a6.webp",982,1356,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f1a4f324032178dbd8dc6e40716f508.webp",981,1354,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/751ed266e5c9cbf49f8c6089628a7907.webp",980,1353]